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Mycophenolate mofetil
(MMF) therapeutic approach
in patients with chronic
glomerulonephritis (GN)
To the Editor: In a recent issue of Kidney International,
Dr. Levin [1] presented successful treatment of patients
with membranoproliferative glomerulonephritis (GN) us-
ing mycophenolate mofetil (MMF). We obtained contra-
dictory results using MMF in five patients with resistant
nephrotic syndrome (NS) during primary GN. MMF (1 g
two times daily) was administered to patients as a second
approach medication (Table 1). Before MMF therapy,
patients were treated with corticosteroids and cyclophos-
phamide or cyclosporin. Along with MMF, the patients
received hypolipemic treatment, angiotensin-converting
enzyme (ACE) inhibitors, and small doses of corticoste-
roids. In the patients, creatinine clearance was normal and
stable over a period of several years before introduction
of MMF. Positive response was observed in one patient,
while in the other four, even an increase in proteinuria
was observed, despite prolongation of the treatment up to
18 months. In the patient with diagnosis of focal segmental
glomerulosclerosis (FSGS), a marked rise in proteinuria
and a decrease in creatinine clearance was observed, with
aggravation of renal insufficiency requiring dialysis a year
and a half after discontinuation of therapy. The only MMF-
sensitive patient in our study was a female with a 13-year
history of renal disease who continued to be in remission
one year after the MMF treatment was concluded. Re-
sults of our study are, therefore, substantially different
from earlier reports [2, 3]. The coexisting major lipid and
protein disorders, along with low gammaglobulin con-
centrations, were likely to contribute to increased risk
of infections, which resulted in an increase of proteinuria
and resistance to treatment. In light of the above, the
Table 1. Characteristics of patients before and after MMF therapy
Proteinuria Creatinine Serum protein Serum albumin
g/24 hours clearance mL/min g/dL g/dL
Patient Diagnosis/duration
age/gender of disease years Before After Before After Before After Before After
E.W. 24/M MGN 3 8.5 9.4 108 101 5.0 4.0 2.7 2.0
B.M. 25/F FSGS 4 6.2 14 99 50 5.0 3.8 2.5 1.6
M.S. 23/F MGN 13 5.4 2.0 100 124 6.0 6.6 3.0 4.3
I.W. 28/M FSGS 16 10 10.8 200 189 5.8 5.6 3.1 3.0
J.K. 19/F MGN 2 4.7 6.4 83 70 3.6 4.4 2.3 2.4
Abbreviations are: MGN, mesangial proliferative glomerulonephritis; MMF, mycophenolate mofetil; FSGS, focal segmental glomerulosclerosis.
use of MMF in treatment of primary GN remains contro-
versial.
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Impact of thyroid dysfunction
on serum cystatin C
To the editor: In the May 2003 issue of Kidney Interna-
tional, Fricker et al [1] reported that thyroid dysfunction
has an impact on serum cystatin C levels. Cystatin C is
an endogenous marker of kidney function that has become
more and more popular in clinical practice and is believed
to be less variable in production and secretion than creati-
nine [2]. Moreover, in contrast to endogenous creatinine
clearance, assessment of cystatin C does not include urine
collections, which provides an advantage in clinical prac-
tice for it is easier to perform and excludes pre-analytic
sampling errors.
While it was shown that thyroid hormone levels in-
versely correlate with serum creatinine levels [3], Fricker
et al [1] demonstrate in their study that thyroid hormone
levels directly correlate with cystatine C levels. Conse-
quently, when considering cystatine C levels, glomerular
filtration rate is most likely overestimated in hypothyroid-
ism and underestimated in hyperthyroidism.
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In a recent study by our group, rats with severe hypothy-
roidism showed signs of renal failure such as increased
blood urea nitrogen, increased creatinine, and decreased
creatinine clearance [4], whereas cystatin C levels were not
significantly different between groups (unpublished data).
This is particularly interesting since renal dysfunction in
euthyroid rats has previously been shown to be associ-
ated with markedly increased cystatin C [5]. The lack of
cystatin C changes in rats with hypothyroid renal failure
underlines the notion of Fricker et al [1] to consider
cystatin C with some caution when thyroid dysfunction
is present.
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